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planning systems: Varian's Eclipse for extracranial treatments 
and with Brainlab's iplan for intracranial treatments. 
Results: Output factors of 1000 SRS agreed with semiflex 
measurements for field size between 3x3cm² and 10x10 cm². 
The larger deviations were observed for the 1x1 cm² field 
size: compared to microDiamond, deviations of 1.6%, 2.5%, 
1.7% and 3.3% were observed for 6, 10 MV FF and 6, 10 MV 
FFF respectively. For the 2x2 cm² field size, deviations were 
less than 1.5% for 6 MV FF and 6 MV FFF and 2.5% for 10 MV 
FF and 10 MV FFF. The 1000 SRS showed large dependent 
dose rate response. This effect was about 1% for 6, 10 MV FF 
and increased to 2.5% for 6 MV FFF and 4% for 10 MV FFF. 
Stereotactic treatment plans gave excellent agreement with 
more than 95% of pixels passing 2%/2mm gamma criteria.  
 
Conclusions: The 4D octavius phantom with associated 1000 
SRS ionization chamber array could be used for stereotactic 
pretreatment QA of FF and FFF beams. It is however 
mandatory to calibrate 1000 SRS for a field size and a dose 
rate close to the patient treatment plan. 
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Purpose/Objective: When ArcCHECK (Sun Nuclear Corp., 
Melbourne, FL) is used for Quality Assurance (QA) on helical 
Tomotherapy treatment plans, Tomotherapy measurement 
mode is applied and there is no correction on diode response 
for field size dependency. It is recommended to use a 
standard size 40x5 cm2 of Tomotherapy static beam for 
ArcCHECK absolute dose calibration . Under such dose 
calibration ArcCHECK measurement does not produce good 
result for helical treatment plan with small target (dimension 
< 3 cm) and high modulation factor (>2.5), with gamma 
passing rate (3% dose, 3 mm distance to agreement) normally 
below 85% in absolute dose comparison. During such helical 
treatment, there are fast and frequent movement of small 
number of MLC leaves while the gantry is rotating. It is 
similar to small field irradiation at many different gantry 
angles. Solid state diodes on the ArcCHECK are slightly 
energy dependent and more sensitive to low energy 
component of the treatment beam. As the energy spectrum 
of treatment beam changes for small field size, the 
sensitivity of the diodes changes correspondingly. In this work 
the ArcCHECK measurements were done on 10 helical 
Tomotherapy treatment plans with small target and high 
modulation factor, with ArcCHECK calibrated under standard 
field (40x5 cm2) and small field (2x2cm2) treatment beam 
respectively to demonstrate if it is necessary to do small field 
dose calibration on ArcCHECK for such Tomotherapy 
treatment QA. 
Materials and Methods; 10 helical Tomotherapy treatment 
plans, with small target size (dimension < 3cm) and high 
modulation factor (>2.5), were used in the study. ArcCHECK 
absolute dose calibration was done initially with a standard 
field (40x5 cm2) and 0.057 cc ionization chamber (A1SL, 
Standard Imaging Inc, Middleton, WI). Absolute point dose 
measurements were also done by placing A1SL ionization 
chamber at the centre of the ArcCHECK with PMMA insert. 
After ArcCHECK measurement on these 10 helical treatment 
plans, absolute dose comparisons between the measurement 
and planning calculation were carried out with gamma test 
(3% dose, 3 mm). The measurements were repeated with 
ArcCHECK calibrated under small field 2x2cm2. The 
difference between the responses of the chamber in the 
standard field and small field 2x2cm2 was corrected in small 
field calibration. 
Results: Absolute point dose measurements for all plans 
showed good agreement with planning calculation as the 
differences were all within ± 2%. When standard field size 
(40x5 cm2) calibration was used, the gamma passing rate of 
ArcCHECK measurements were below 85% (Mean=79.5%, 
S.D.=3.3%) for all plans. When small field (2x2cm2) dose 
calibration was used instead, the gamma passing rates for all 
plans were over 90% (Mean=93.7%, S.D.=1.8%). 
Conclusions: Sensitivity of the diode changes for small 
irradiation field. Small field (2x2cm2) dose calibration on 
ArcCHECK should be used instead when measuring helical 
Tomotherapy treatment with small target and high 
modulation factor in order to correct such sensitivity change.  
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Purpose/Objective: Stereotactic radiation therapy 
(SRS/SBRT) require a more comprehensive quality assurance 
(QA) program than 3DCRT and IMRT (or VMAT), especially 
because of its very high-dose gradients. The purpose of this 
study is to test a IBA 3D dosimetry analysis package, COMPASS 
3.0 with MatriXXEvolution ion chamber array, for SRS/SBRT pre-
treatment verification in terms of 3D dose, gamma analysis, 
Target and OAR structures DVH. 
Materials and Methods: Nine treatment plans (SRS/SBRT) 
with different dose fractionations have been selected: 3 
brain cases (2 cases of 21Gy x 1 and one of 15Gy x 1), 3 liver 
cases (15Gy x 3) and 3 lung cases (2 cases of 15 Gy x 3 and 
one of 8 Gy x 4). All measurements, performed with 
COMPASS, were compared with the reference dose 
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distributions calculated in Eclipse TPS; for the evaluation of 
pre-treatment verification agreement, D100% , DMean and D1% and 
local γ analysis (2mm/2% - 3mm/3%) were investigated for 
CTV, PTV and OARs. The same cases were analyzed, in terms 
of γ analysis (2mm/2% - 3mm/3%) with our routinely pre-
treatment verification system, based on EPID images and 
EPIQA software. Finally to test systems robustness, 
intentional errors have been introduced to the original 
position for one of the SBRT plans, in a first step closing the 
X1 jaw, then opening a single leaf. 
Results: Average differences, between Eclipse TPS and 
Compass reconstruction, in terms of D100% , DMean and D1% for 
PTV result, respectively, 3.0 %, 1.9 %, 2.1 % for liver, 1.9 %, 
1.1 % and 2.1 % for brain, 13 %, 4.2 % and 1.8 % for lung. 
Fig. 1 shows the worst scenario found in terms of differences 
between calculated and measured dose distribution; in this 
case local γ test fails for PTV and CTV (86,5 % and 82 %): it's 
due to a difference of +4 % in absolute dose inside the CTV. 
Even if this result could be not acceptable with conventional 
pre-treatment verification devices, the chance to investigate 
about dose differences inside the target and OAR, could be 
really interesting from a clinical point of view. For the same 
case the number of point with γ<1, found with EPIQA, is 96 %. 
 
 
Fig. 1 
Tab. 1 shows detected errors with two systems in terms of 
differences in D100% and D50%, respect to the reference correct 
plan. 
 
Tab. 1 
 
Conclusions: This work confirms that gamma approach for 
pre-treatment verifications could be not enough sensitive to 
decide about delivery. A system like Compass gives more 
completed information in terms of 3D dose distribution and 
DVH taking into account patients anatomy; it seems to be 
also capable to detect possible errors. 
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Purpose/Objective: The purpose of EPID in vivo dosimetry is 
to verify whether the predicted and delivered dose agree, 
both in terms of absolute dose and geometrical deposition. 
Dedicated software, the in vivo 3D DC (Dosimetry Check) 
system (Math Resolutions, Columbia), was implemented at 
our hospital to replace our pretreatment D4 (Delta4) system 
(Scandidos, Uppsala). 
Materials and Methods: Math Resolutions was provided with 
output factors and dose profiles to model the dose kernels 
for our linear accelerators. Deconvolution kernels were 
created by measuring transit dose with the linac specific EPID 
panel for different field sizes at different thicknesses of 
water. The DC software handles 2 modes of operation. For 
transit dosimetry, the patient attenuated fluence is acquired 
during clinical treatment. For pretreatment dosimetry, the 
un-attenuated fluence is acquired. The main limiting factor 
of the system is the size of the sensitive region of the EPID 
panel (30x40 cm2 for Varian and 41x41 cm2 for Elekta). Since 
the height of the Varian EPID panel is variable, treatment 
plans with a larger field size can be measured as a 
pretreatment plan at a smaller SID. 
Results: A tissue-equivalent polystyrene CarPet phantom of 
20 cm thickness was used for the validation of the DC system. 
An agreement within 5% of the isocentric treatment plan 
dose was obtained for every clinically used combination of 
TPS and linac. Gamma criteria of 3mm/3% with pass/fail 
criteria of 95% for fixed-beam IMRT and 90% for VMAT have 
been used at our department for measurements on the 
presumed homogeneous D4 phantom. For pretreatment DC 
dosimetry, relaxed gamma criteria of 3mm/6% were applied 
since the dose is reconstructed on the heterogeneous CT-
based model of the patient. Taking into account setup errors 
inaccuracies and patient anatomy uncertainties, gamma 
criteria of 5mm/6% were used for transit DC dosimetry. For 
both systems, a threshold of 20% of the prescribed dose was 
applied to exclude false positive influences of low dose 
regions. For lung cases, the pencil beam algorithm used in DC 
did not meet our requirements for accurate dose 
reconstruction. Therefore, we applied a density override in 
the patient lung region in both dose planning and DC dose 
reconstruction of pretreatment measurements. Primary test 
results suggest a better congruence with D4 γ results and 
with the acceptance isocentre dose difference (DD) 
specifications (overview in Table 1). 
